"With its outstanding deliverability, conformability and visibility, the PROMUS Element Stent offers interventional cardiologists an exceptional stenting option for patients with coronary artery disease," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. "These data confirm consistent long term performance which supports our efforts to improve the lives of patients around the world."
Separately, Jeffrey Popma, M.D., Beth Israel Deaconess Medical Center, Boston, presented data that demonstrated significantly less vessel straightening, which may be associated with improved blood flow within the vessel, when using the conformable PROMUS Element Stent compared to the more rigid Xience V stent (40 percent relative reduction in angulation change from pre to post procedure with PROMUS Element, P=0.01).
"The PLATINUM three-year results support the theory that platform matters," said Popma. "The flexible and conformable platinum chromium PROMUS Element Stent causes less vessel straightening than Xience stents, possibly contributing to the low clinical event rates observed at three years with PROMUS Element Stents."
The PROMUS Element Stent, utilized in the PROMUS Element Stent System and the PROMUS Element™ Plus Stent System, uses a proprietary platinum chromium alloy designed specifically for coronary stenting, which enables enhanced visibility, less recoil, high fracture resistance, excellent conformability and higher radial strength. The PROMUS Element Plus Stent System features an advanced low-profile delivery system to facilitate precise delivery of the stent across challenging lesions.Boston Scientific received CE Mark approval for the PROMUS Element Stent System in 2009 and for the PROMUS Element Plus Stent System in 2011. The PROMUS Element Plus Stent System was approved by the U.S. Food and Drug Administration in 2011. Xience V is a trademark of the Abbott Laboratories group of companies. About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, clinical trials and impact of results, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts